_id
690daa00ccc777a4e85d088f
Ticker
ADTX
Name
Aditxt Inc.
Exchange
NASDAQ
Address
2569 Wyandotte Street, Mountain View, CA, United States, 94043
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.aditxt.com
Description
Aditxt, Inc., a commercial-stage company, discovers and develops products in the areas of immune health, precision health, population health, women's health, and neurologic health. The company develops AditxtScore that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.
Last Close
2.37
Volume
2426056
Current Price
2.24
Change
-5.485232067510544
Last Updated
2025-11-28T11:52:39.187Z
Image
data:image/webp;base64,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
Ipo Date
2020-06-30T00:00:00.000Z
Market Cap
1756654
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Rating
4
Target Price
61
Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
748
Cost Of Revenue
68263
Gross Profit
-67515
Operating Expenses
3073115
Operating Income
-3140630
Interest Expense
176527
Pretax Income
-24207669
Net Income
-24045405
Eps
-548.7813812306007
Dividends Per Share
1354774
Shares Outstanding
559444
Income Tax Expense
-
EBITDA
-23963611
Operating Margin
-419870.32085561496
Total Other Income Expense Net
-21067039
Cash
163041
Short Term Investments
-
Receivables
39182
Inventories
6572
Total Current Assets
420438
Property Plant Equipment
2048792
Total Assets
11799639
Payables
10363097
Short Term Debt
5526130
Long Term Debt
-
Total Liabilities
20658817
Equity
-7732728
Depreciation
67799
Change In Working Capital
829285
Cash From Operations
-2344554
Capital Expenditures
0
Cash From Investing
2425000
Cash From Financing
2183916
Net Change In Cash
-160638
PE
-
PB
-0.012692524552783961
ROE
310.95630157946846
ROA
-203.78085295660316
FCF
-2344554
Fcf Percent
-3134.4304812834225
Piotroski FScore
1
Health Score
31
Deep Value Investing Score
0.5
Defensive Investing Score
5.5
Dividend Investing Score
1.5
Economic Moat Investing Score
6.3
Garp Investing Score
2.5
Growth Investing Score
2.5
Momentum Investing Score
5
Net Net Investing Score
0.5
Quality Investing Score
2.5
Value Investing Score
2.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
748
Quarters > 0 > income Statement > cost Of Revenue
68263
Quarters > 0 > income Statement > gross Profit
-67515
Quarters > 0 > income Statement > operating Expenses
3073115
Quarters > 0 > income Statement > operating Income
-3140630
Quarters > 0 > income Statement > interest Expense
176527
Quarters > 0 > income Statement > pretax Income
-24207669
Quarters > 0 > income Statement > net Income
-24045405
Quarters > 0 > income Statement > eps
-548.7813812306007
Quarters > 0 > income Statement > dividends Per Share
1354774
Quarters > 0 > income Statement > shares Outstanding
43816
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-23963611
Quarters > 0 > income Statement > operating Margin
-419870.32085561496
Quarters > 0 > income Statement > total Other Income Expense Net
-21067039
Quarters > 0 > balance Sheet > cash
163041
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
39182
Quarters > 0 > balance Sheet > inventories
6572
Quarters > 0 > balance Sheet > total Current Assets
420438
Quarters > 0 > balance Sheet > property Plant Equipment
2048792
Quarters > 0 > balance Sheet > total Assets
11799639
Quarters > 0 > balance Sheet > payables
10363097
Quarters > 0 > balance Sheet > short Term Debt
5526130
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
20658817
Quarters > 0 > balance Sheet > equity
-7732728
Quarters > 0 > cash Flow > net Income
-24449825
Quarters > 0 > cash Flow > depreciation
67799
Quarters > 0 > cash Flow > change In Working Capital
829285
Quarters > 0 > cash Flow > cash From Operations
-2344554
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
2425000
Quarters > 0 > cash Flow > cash From Financing
2183916
Quarters > 0 > cash Flow > net Change In Cash
-160638
Quarters > 0 > ratios > PE
-548.7813812306007
Quarters > 0 > ratios > PB
-0.012692524552783961
Quarters > 0 > ratios > ROE
310.95630157946846
Quarters > 0 > ratios > ROA
-203.78085295660316
Quarters > 0 > ratios > FCF
-2344554
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-3134.4304812834225
Quarters > 0 > health Score
31
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
1004
Quarters > 1 > income Statement > cost Of Revenue
68886
Quarters > 1 > income Statement > gross Profit
-67882
Quarters > 1 > income Statement > operating Expenses
6084513
Quarters > 1 > income Statement > operating Income
-6152395
Quarters > 1 > income Statement > interest Expense
1259598
Quarters > 1 > income Statement > pretax Income
-7395658
Quarters > 1 > income Statement > net Income
-7256808
Quarters > 1 > income Statement > eps
-390.1694273707574
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
18599.12
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-6068178
Quarters > 1 > income Statement > operating Margin
-612788.3466135459
Quarters > 1 > income Statement > total Other Income Expense Net
-1243263
Quarters > 1 > balance Sheet > cash
323679
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
39743
Quarters > 1 > balance Sheet > inventories
7617
Quarters > 1 > balance Sheet > total Current Assets
433655
Quarters > 1 > balance Sheet > property Plant Equipment
2298290
Quarters > 1 > balance Sheet > total Assets
32691232
Quarters > 1 > balance Sheet > payables
9680600
Quarters > 1 > balance Sheet > short Term Debt
5369085
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
20696368
Quarters > 1 > balance Sheet > equity
12959050
Quarters > 1 > cash Flow > net Income
-7395658
Quarters > 1 > cash Flow > depreciation
67882
Quarters > 1 > cash Flow > change In Working Capital
3295148
Quarters > 1 > cash Flow > cash From Operations
-2384737
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
-2425000
Quarters > 1 > cash Flow > cash From Financing
4657000
Quarters > 1 > cash Flow > net Change In Cash
-152737
Quarters > 1 > ratios > PE
-390.1694273707574
Quarters > 1 > ratios > PB
0.003214898376038367
Quarters > 1 > ratios > ROE
-55.99799368009229
Quarters > 1 > ratios > ROA
-22.198025452206878
Quarters > 1 > ratios > FCF
-2384737
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-2375.2360557768925
Quarters > 1 > health Score
24
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
1018
Quarters > 2 > income Statement > cost Of Revenue
734
Quarters > 2 > income Statement > gross Profit
284
Quarters > 2 > income Statement > operating Expenses
5608399
Quarters > 2 > income Statement > operating Income
-5608115
Quarters > 2 > income Statement > interest Expense
357783
Quarters > 2 > income Statement > pretax Income
-5952465
Quarters > 2 > income Statement > net Income
-5710309
Quarters > 2 > income Statement > eps
-917.0049444928884
Quarters > 2 > income Statement > dividends Per Share
1354774
Quarters > 2 > income Statement > shares Outstanding
6227.13
Quarters > 2 > income Statement > income Tax Expense
-242156
Quarters > 2 > income Statement > EBITDA
-5525399
Quarters > 2 > income Statement > operating Margin
-550895.3831041257
Quarters > 2 > income Statement > total Other Income Expense Net
-344350
Quarters > 2 > balance Sheet > cash
476416
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
672223
Quarters > 2 > balance Sheet > inventories
9057
Quarters > 2 > balance Sheet > total Current Assets
1220312
Quarters > 2 > balance Sheet > property Plant Equipment
2539389
Quarters > 2 > balance Sheet > total Assets
31222036
Quarters > 2 > balance Sheet > payables
6654132
Quarters > 2 > balance Sheet > short Term Debt
3795463
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
15458038
Quarters > 2 > balance Sheet > equity
16589334
Quarters > 2 > cash Flow > net Income
-5710309
Quarters > 2 > cash Flow > depreciation
69283
Quarters > 2 > cash Flow > change In Working Capital
-6027352
Quarters > 2 > cash Flow > cash From Operations
-11713395
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
-
Quarters > 2 > cash Flow > cash From Financing
11356780
Quarters > 2 > cash Flow > net Change In Cash
-356615
Quarters > 2 > ratios > PE
-917.0049444928884
Quarters > 2 > ratios > PB
0.0008408276787965087
Quarters > 2 > ratios > ROE
-34.42156870191413
Quarters > 2 > ratios > ROA
-18.28935499273654
Quarters > 2 > ratios > FCF
-11713395
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-11506.281925343812
Quarters > 2 > health Score
29
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
3175
Quarters > 3 > income Statement > cost Of Revenue
71005
Quarters > 3 > income Statement > gross Profit
-67830
Quarters > 3 > income Statement > operating Expenses
5583203
Quarters > 3 > income Statement > operating Income
-5651033
Quarters > 3 > income Statement > interest Expense
310963
Quarters > 3 > income Statement > pretax Income
-5547172
Quarters > 3 > income Statement > net Income
-5226628
Quarters > 3 > income Statement > eps
-11379.551491399956
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
459.3
Quarters > 3 > income Statement > income Tax Expense
5333578000
Quarters > 3 > income Statement > EBITDA
-5069841
Quarters > 3 > income Statement > operating Margin
-177985.29133858267
Quarters > 3 > income Statement > total Other Income Expense Net
103861
Quarters > 3 > balance Sheet > cash
833031
Quarters > 3 > balance Sheet > short Term Investments
832197969
Quarters > 3 > balance Sheet > receivables
1152186
Quarters > 3 > balance Sheet > inventories
11245
Quarters > 3 > balance Sheet > total Current Assets
1999841
Quarters > 3 > balance Sheet > property Plant Equipment
2773555
Quarters > 3 > balance Sheet > total Assets
32144390
Quarters > 3 > balance Sheet > payables
10192373
Quarters > 3 > balance Sheet > short Term Debt
6484035
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
23857994
Quarters > 3 > balance Sheet > equity
8869576
Quarters > 3 > cash Flow > net Income
-5547172
Quarters > 3 > cash Flow > depreciation
166368
Quarters > 3 > cash Flow > change In Working Capital
-632019
Quarters > 3 > cash Flow > cash From Operations
-6146990
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
-2740000
Quarters > 3 > cash Flow > cash From Financing
9391425
Quarters > 3 > cash Flow > net Change In Cash
504435
Quarters > 3 > ratios > PE
-11379.551491399956
Quarters > 3 > ratios > PB
0.00011599562369159474
Quarters > 3 > ratios > ROE
-58.927596989980124
Quarters > 3 > ratios > ROA
-16.259845030501435
Quarters > 3 > ratios > FCF
-6146990
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-1936.059842519685
Quarters > 3 > health Score
19
Valuation > metrics > PE
-548.7813812306007
Valuation > metrics > PB
-0.012692524552783961
Valuation > final Score
50
Valuation > verdict
Fair
Profitability > metrics > ROE
310.95630157946846
Profitability > metrics > ROA
-5719.132190715397
Profitability > metrics > Net Margin
-32146.263368983957
Profitability > final Score
40
Profitability > verdict
Weak
Risk > metrics > Interest Coverage
-17.79121607459482
Risk > final Score
-41
Risk > verdict
High
Liquidity > metrics > Current Ratio
0.026460569793609216
Liquidity > metrics > Quick Ratio
0.026046956217568043
Liquidity > final Score
11
Liquidity > verdict
Weak
Prev Valuations > 0
70
Prev Valuations > 1
70
Prev Valuations > 2
70
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
10
Prev Risks > 1
-15
Prev Risks > 2
-55
Prev Liquidities > 0
11
Prev Liquidities > 1
16
Prev Liquidities > 2
16
Updated At
2025-12-14T00:12:00.428Z
Aditxt, Inc., a commercial-stage company, discovers and develops products in the areas of immune health, precision health, population health, women's health, and neurologic health. The company develops AditxtScore that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.
Stock Price
$ 0.00
0% decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ACritical Analysis: Addex Therapeutics (NASDAQ:ADXN) & Aditxt (NASDAQ:ADTX) - Defense World
12/14/2025
Critical Analysis: Addex Therapeutics (NASDAQ:ADXN) & Aditxt (NASDAQ:ADTX) Defense World
Read more →$ADTX stock is down 21% today. Here's what we see in our data. Quiver Quantitative
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
BUY
Target Price:
$61
Analyst Picks
Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very High
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
* Institutions hold a combined 0.79% of the total shares of Aditxt Inc.
1.
Virtu Financial LLC(0.4175%)
since
2025/06/30
2.
HRT FINANCIAL LLC(0.2704%)
since
2025/06/30
3.
Tower Research Capital LLC(0.0809%)
since
2025/06/30
4.
Morgan Stanley - Brokerage Accounts(0.0141%)
since
2025/06/30
5.
UBS Group AG(0.0027%)
since
2025/06/30
6.
SBI Securities Co Ltd(0.0018%)
since
2025/06/30
7.
IFP Advisors, LLC(0.0008%)
since
2025/06/30
8.
Bank of America Corp(0.0004%)
since
2025/06/30
9.
Advisor Group Holdings, Inc.(0.0001%)
since
2025/06/30
10.
Group One Trading, LP(0%)
since
2025/06/30
11.
Harwood Advisory Group, LLC(0%)
since
2025/06/30
12.
JONES FINANCIAL COMPANIES LLLP(0%)
since
2025/06/30
13.
Goldman Sachs Group Inc(0%)
since
2025/03/31
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.